ENHANCE: A study for individuals with untreated higher-risk myelodysplastic syndrome (MDS)

ENHANCE is a clinical research study investigating magrolimab plus azacitidine versus azacitidine plus placebo to treat higher-risk untreated MDS.

Selected Eligibility Criteria

18 years of age or older
Previously untreated intermediate- to very high-risk MDS
No prior treatment with CD47- or SIRPα-targeting agent

If you are interested in participating in ENHANCE and meet these criteria, please talk to your doctor about your eligibility and further details about the study.

Visit ClinicalTrials.gov and search NCT04313881 for more information

The safety, efficacy, and uses of magrolimab have not been established. There is no guarantee that magrolimab will be approved by the FDA or other global health authorities in MDS.

Trial Schematic

Screening: Patients with untreated MDS who are intermediate- to very high-risk by IPSS-R

1:1 Randomization

(N=260)

Magrolimab + Azacitidine
Azacitidine + Placebo

(N=260)

Two Primary Endpoints:

CR Rate
OS

Magrolimab (or saline placebo) dosing:

Cycle 1:

Priming (1 mg/kg) on Days 1 and 4
15 mg/kg on Day 8
30 mg/kg Days 11, 15, 22

Cycle 2:

30 mg/kg Days 1, 8, 15, 22

Cycle 3 & onward:

30 mg/kg on Days 1 and 15

CD, cluster of differentiation; CR, complete remission; IPSS-R, Revised International Prognostic Scoring System; IV, intravenous; SIRPα, signal regulatory protein alpha; MDS, myelodysplastic syndrome; OS, overall survival; SC, subcutaneous.

Gilead and the Gilead Logo are trademarks of Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404 © 2022 Gilead Sciences, Inc. All rights reserved.